The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Fields of Study & Subjects
Chronic Myeloid Leukemia Treatments
Chronic Lymphocytic Leukemia Research
Acute Myeloid Leukemia Research
Publication details
- Journal / source
- Leukemia
- Volume
- 40
- Issue
- 5
- Pages
- 1080–1082
- Publication date
- 30 March 2026
- Language
- EN